02351nas a2200325 4500000000100000008004100001260001300042653001000055653000900065653002200074653002600096653003000122653001100152653002300163653001100186653000900197653001600206653001600222653001400238653001300252100001300265700001400278700001400292245009400306856005500400300001000455490000800465520153800473022001402011 2009 d c2009 Jul10aAdult10aAged10aAged, 80 and over10aAnti-Bacterial Agents10aDrug Therapy, Combination10aFemale10aGranuloma Annulare10aHumans10aMale10aMiddle Aged10aMinocycline10aOfloxacin10aRifampin1 aMarcus D1 aMahmoud B1 aHamzavi I00aGranuloma annulare treated with rifampin, ofloxacin, and minocycline combination therapy. uhttp://archderm.ama-assn.org/cgi/reprint/145/7/787 a787-90 v1453 a
BACKGROUND: Granuloma annulare (GA) is a benign, usually self-limiting, dermatosis, that typically presents as asymptomatic, flesh-colored or erythematous papules, frequently arranged in an annular or arciform pattern on the distal extremities. Although localized GA is most commonly observed, a generalized or disseminated form can occur. The etiology of GA is unknown; however, multiple inciting factors have been proposed. Histologically, GA is characterized by foci of degenerative collagen associated with palisading, sometimes infiltrating granulomatous inflammation.
OBSERVATIONS: We report 6 cases with biopsy-proved GA, resistant to the standard modalities of treatment that resolved after 3 months with monthly rifampin (600 mg), ofloxacin (400 mg), and minocycline hydrochloride (100 mg) combination therapy. Rifampin, ofloxacin, and minocycline combination therapy has been successfully used to treat patients with paucibacillary leprosy. Given reports that prolonged antibiotic agents are a useful treatment for GA, rifampin (600 mg), ofloxacin (400 mg), and minocycline hydrochloride (100 mg) combination therapy was initiated in these patients. Complete clearance of the plaques was achieved 3 to 5 months after the initiation of treatment. Some patients experienced postinflammatory hyperpigmentation.
CONCLUSION: Although our treatment was effective, further studies may be needed to confirm the success of this therapeutic option for patients with recalcitrant lesions of GA.
a1538-3652